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ABSTRACT
Age-related cognitive decline refers to the memory impairment and difficulty learning new
tasks that occurs during the normal process of aging. There are many possible changes that
occur at the neuronal level that could account for age-related cognitive decline. One
hypothesis suggests that a dysregulation of neuronal intracellular calcium concentration
contributes to age-related cognitive deficits. Previous research suggests that an increase in
neuronal L-type voltage-gated calcium channels (LVGCCs) occurs in the brain during aging.
This increase could account for altered intracellular calcium concentration and lead to agerelated cognitive decline. A line of transgenic mice that over-express the LVGCC CaV1.3 in
the forebrain was developed in order to investigate the relative contribution of this change to
age-related cognitive decline. These animals were also characterized on both on a molecular
and behavioral level. Molecular characterization revealed approximately 20% overexpression of CaV1.3 in the forebrain of transgenic animals, while neurobehavioral
experiments indicate these mice have unimpaired motor function and exploratory behaviors.
Based upon these results, this new line of mice will be an excellent model for studies of agerelated cognitive decline.
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INTRODUCTION
The Aging Population
In America, the population of individuals over the age of 65 is expected to rise from
37.8 million to between 99 and 108 million within the next forty years. The average life
expectancy at birth is expected to rise from 76 years of age to between 82 and 89 years of age
(Olshansky et al., 2009). Currently, forty percent of people over the age of 65 are affected by
deficits in cognition related to aging (Grundman et al., 2004). Based on these data, the
number of individuals experiencing age-related cognitive decline is also likely to rise. Agerelated cognitive decline is primarily characterized by memory impairment and difficulty
learning new tasks. These impairments are a part of the normal process of aging and occur in
the absence of overt pathology, such as Alzheimer’s disease or dementia (Grundman et al.,
2004). Due to the increasing number of individuals experiencing age-related cognitive
decline, development of novel and effective treatments for cognitive loss has become
increasingly important. Therefore, it is critical to determine the underlying molecular
mechanisms of age-related cognitive decline.
The Calcium Dysregulation Hypothesis of Aging
Many changes occur at the neuronal level during the process of normal aging that
may lead to age-related cognitive decline. One change at the molecular level that occurs
during aging is a dysregulation of calcium homeostasis. Khachaturian’s calcium hypothesis
of aging suggests that an alteration in intracellular calcium concentration compromises
downstream homeostatic functions (Khachaturian, 1987). The effects of dysregulation of
calcium homeostasis, including dysfunction in mechanisms that eliminate oxidative stress,
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altered synaptic plasticity, and altered gene transcription, may contribute to premature
neuronal death and cognitive decline (Khachaturian, 1987).
Results of calcium imaging experiments were consistent with Khachaturian's
hypothesis that changes in intracellular calcium levels accompany aging. Intracellular
calcium imaging was performed on hippocampal slices of both young adult (3-5mo.) and
aged (24-27mo.) rats (Thibault et al., 2001). The hippocampus is an area of the brain thought
to play a role in learning and memory that is also sensitive to aging. Ratiometric pseudocolor
images were obtained using the fluorophore Indo-1, which fluoresces when bound to calcium
in the presence of ultraviolet light. Confocal imaging was performed on single hippocampal
neurons while at rest and during trains of action potential firing. At rest, hippocampal
neurons from both young adult and aged rats showed similar low levels of fluorescence,
indicating a low intracellular calcium concentration. Both young and aged neurons showed
an activity-dependent increase in fluorescence, indicating an increase in intracellular calcium
concentration with action potential firing (Thibault et al., 2001). This increase was
significantly larger in aged neurons than in young neurons. Taken together, these results
demonstrate an age-related activity-dependent increase in intracellular calcium, consistent
with Khachaturian’s calcium dysregulation hypothesis of aging.
Calcium and Normal Cell Function
Calcium plays a critical role in normal cell function. It acts as a signaling molecule
for energy production, cell proliferation, gene regulation, and apoptosis (Case et al., 2007).
Many of the cellular functions regulated by calcium influx are performed via secondmessenger signaling cascades. When intracellular calcium levels increase even slightly,
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downstream effects can be greatly amplified. Therefore, it is very important that intracellular
levels of calcium are closely maintained. Intracellular calcium concentrations are regulated
through a series of membrane channels that regulate both influx and efflux, as well as via
intracellular calcium buffering systems (Figure 1). As calcium enters the cell, it is quickly
buffered by calbindin and other buffering proteins (Mattson et al., 2007). Calcium can also
be removed from the cell via the Na+/Ca+ exchange channel in order to maintain a low
intracellular concentration (Mattson et al., 2007). Changes in any of these calcium regulation
processes may lead to altered neuronal function.
In neurons, calcium holds an additional function as a regulator of neuronal activity.
Calcium is critical for signaling at synapses and plays an important role in membrane
excitability and synaptic plasticity (Mattson et al., 2007). Calcium entry into a neuron
activates many kinases and results in the production or activation of many downstream
signaling molecules. One specific example of an important calcium signaling pathway is the
activation of calcium/calmodulin kinase signaling cascades that eventually lead to brainderived neurotrophic factor expression (West et al., 2001). Brain-derived neurotrophic factor
(BDNF) acts as a neuronal survival factor as well as a regulator of synaptic activity (West et
al., 2001). Therefore, changes in intracellular calcium may lead to altered expression of
BDNF, leading to alterations of neuronal signaling. Calcium also induces neurotransmitter
release when voltage-dependent and ligand-gated calcium channels open at presynaptic
terminals (Mattson et al., 2007). In a normal state, intracellular calcium concentration is
significantly lower than the extracellular concentration, causing rapid influx when calciumpermeable ion channels are open. In conclusion, calcium plays an important role in many
vital functions within neurons. Therefore, changes in calcium channels themselves can lead
3

Figure 1. Regulation of intracellular calcium homeostasis. Intracellular calcium influx
occurs via L-type voltage-gated calcium channels as well as NMDARs, whereas efflux
occurs via the sodium-calcium transporter. Calcium that has entered a cell can also be
buffered via binding proteins such as calbindin and calnexin, or by the endoplasmic
reticulum and mitochondria.
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to dysregulation of intracellular calcium concentrations, contributing to aberrant neuronal
function and cognitive decline.
L-Type Voltage-Gated Calcium Channels and Aging
Alterations in calcium buffering, influx, or efflux could account for the dysregulation
of intracellular calcium that accompanies aging. One possible explanation for the
dysregulation of calcium concentration is the up-regulation of neuronal calcium channel
expression. There are a number of routes for neuronal calcium influx, including calcium
influx through L-type voltage-gated calcium channels (LVGCCs).
Several subunits make up a complete LVGCC, including the α1, α2δ, β and γ subunits
(Figure 2). The ion-conducting pore-forming subunit of the complex is the α1 subunit
(Lipscombe et al., 2004). The remaining subunits interact with other proteins and calcium
channel antagonists, as well as modulate activity of the α1 subunit (Lai et al., 2006). Two
types of LVGCCs are expressed in the brain: CaV1.2 and CaV1.3 (Lipscombe et al., 2004).
These ion channels are characterized by their activation via strong depolarization of the
neuron. L-type voltage-gated calcium channels exhibit slow activation kinetics and calciumdependent inactivation. The nomenclature "L-type" refers to the "large and long-lasting"
current originally described during LVGCC activation. Dihydropyridines are calcium
channel antagonists that block calcium flow through the LVGCCs. The dihydropyridines
nimodipine and nifedipine are commonly used as antagonists to inactivate LVGCCs
(Lipscombe et al., 2004).
LVGCCs are involved in control of neuronal excitability. Neuronal excitability refers
to the ability of a neuron to evoke action potentials. This excitability is, in part, controlled by
rises in intracellular calcium that occur after periods of neuronal activity. After an action
5

Figure 2. Diagram of L-type voltage-gated calcium channel. An LVGCC is made up of
four subunits, the α1, α2, β, γ and δ subunits. The α1 subunit forms the ion-conducting pore,
while the remaining subunits are responsible for interactions with other proteins and calciumchannel antagonists, as well as regulate the α1 subunit (Lai et al., 2006).
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potential or series of action potentials, known as a "burst," has occurred, there is a rise in
intracellular calcium concentration. Calcium-activated potassium channels then open,
causing a rapid efflux of potassium into the neuron. The efflux of potassium hyperpolarizes
the cell, causing what is known as the post-burst afterhyperpolarization (AHP) (Toescu et al.,
2010). The neuron must return from the hyperpolarized state to resting potential before again
activating, which suppresses neuronal excitability.
There are three phases of the AHP: the fast AHP (fAHP), the medium AHP (mAHP),
and the slow AHP (sAHP). The fAHP occurs immediately after an action potential, lasting
for about 10ms. The mAHP occurs approximately between 10ms and 100ms after a neuron
has fired. The sAHP occurs after a series of action potentials and can last from around 100ms
up to 1s post-burst (Toescu et al., 2010). It is known that the sAHP is calcium-dependent, as
a sAHP decrease has been seen after blocking of LVGCCs using dihydropyridines (Campbell
et al., 1996). The sAHP plays a role in slowing the discharge rate of action potentials (Nicoll
et al., 1988). A large sAHP greatly lowers neuronal excitability, due to the longer duration of
time before the neuron re-polarizes to normal resting potential.
The Afterhyperpolarization and Aging
One experiment describing the AHP in aged animals was performed on hippocampal
slices of young (3mo.) and aged (36+ mo.) rabbits (Moyer et al., 1992). The experiment
found that the slow AHP in the hippocampus of aged rabbits was significantly larger than
that of young rabbits. Furthermore, an addition of nimodipine decreased the AHP in an agedependent manner in the hippocampus of aged rabbits. The addition of nimodipine also
increased neuronal excitability in an age-dependent manner (Moyer et al., 1992; Disterhoft et
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al., 1996). These experiments indicate that both the increase in AHP and decrease in neuronal
excitability that occur in the hippocampus of aged animals are LVGCC-dependent.
A correlation has also been found between learning impairments and decreased
neuronal excitability in aged rats. Young (3-4 mo.) and aging (29-31 mo.) rats were trained in
trace eyeblink conditioning, a task used to study learning in both animals and humans. Rats
were conditioned to a tone paired with an air puff to the eye. Animals that learned the task
were animals that blinked within 100ms preceding the air puff. After conditioning, brain
slices were prepared from the rats and the AHP was recorded in the hippocampus. Aged rats
that were unable to learn the task had a large sAHP, whereas aged rats that learned the task
had a sAHP of similar size to that of young animals (Matthews et al., 2009).
LVGCCs have been studied in aged rats. A LVGCC agonist, BayK8466, was used on
hippocampal slices to augment the L-type current. The neurons were depolarized to 10mV
from a holding potential of -70mV. The average total current was recorded in hippocampal
slices of young adult, middle-aged, and aged rats. During both depolarization and
repolarization, the L-type current was increased in aged animals (Thibault and Landfield,
1996). This result supports the hypothesis that during aging there is an increase in LVGCC
current. Furthermore, the density of available LVGCCs was calculated during the experiment
and was found to be significantly higher in aged rats than in young adult or middle aged rats
(Thibault and Landfield, 1996).
The previously discussed experiments strongly suggest that LVGCCs play a role in
decreased neuronal excitability in aged animals. However, these experiments did not
determine which LVGCC, CaV1.2 or CaV1.3, was over-expressed during aging and caused an
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increase in the AHP. This ambiguity is due to the similar pharmacology of CaV1.2 and
CaV1.3 (Gamelli et al., 2011). While dihydropyridines block LVGCCs in general, no specific
antagonist is available to target either CaV1.2 or CaV1.3 individually. In order to circumvent
non-specificity of LVGCC antagonists, knockout (KO) mice of each brain-specific LVGCC
were developed. Brain slices were prepared from knockout mouse models of CaV1.2 or
CaV1.3. Experiments were performed in the hippocampus to determine which LVGCC
contributes to the sAHP (Gamelli et al., 2011). When CaV1.2 was knocked out, the sAHP in
KO animals vs. wild-type animals was not diminished. This result indicates that CaV1.2 is
not involved in the sAHP in the hippocampus of young mice. However, the sAHP in
CaV1.3KO animals was significantly diminished compared to wild-type counterparts,
suggesting that CaV1.3 plays a role in the slow afterhyperpolarization (Gamelli et al., 2011).
One caveat to this study is that it was not performed on aged animals, therefore, it has been
extrapolated that knocking out CaV1.3 in aged mice would result in a diminished sAHP in the
hippocampus compared to that of age-matched wild-type counterparts.
Based on the preceding evidence, a transgenic mouse model was developed with the
purpose of studying the relative contribution of CaV1.3 to the increase in AHP and cognitive
deficits that accompany the process of normal aging. This mouse model was designed to
over-express CaV1.3, mimicking LVGCC over-expression previously found in aged rats.
This model is referred to as CaV1.3HA because of an HA tag located on the CaV1.3
transgene. A forebrain-specific transgenic promoter, alpha calcium/calmodulin kinase II, was
exploited to localize transgene overexpression to the area of the brain affected by aging that
is also associated with learning and memory (Mayford et al., 1996). It is hypothesized that
young CaV1.3HA mice will exhibit cognitive deficits similar to the deficits found in wild9

type aged mice. Before utilizing this new line of mice as a model of aging, it is imperative to
examine the molecular characteristics of CaV1.3 over-expression. Transgenic mice also need
to be examined in basic neurobehavioral tests to determine if transgene presence affects
normal brain function and behaviors. The work presented herein describes the development
as well as a molecular and basic neurobehavioral characterization of this new mouse model
of aging.
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MATERIALS AND METHODS
Transgene Construction
Two plasmids contained the DNA components necessary for creating the CaV1.3HA
transgene. The first plasmid (pMM403; a gift from M. Mayford, SCRIPPS, CA) (Mayford et
al., 1996) contained a sequence of the 5’ UTR (approximately 8.5kb) isolated from the
upstream region of rat alpha Ca2+/calmodulin-dependent protein kinase II, αCaMKII, which
contained the promoter element (Mayford et al., 1996). A characterization utilizing this 8.5kb
5’UTR demonstrated that the αCaMKII promoter effectively localizes transgene expression
in the forebrain (Mayford et al., 1996). Furthermore, protein expression of αCaMKII begins
postnatally, with expression beginning around day four and leveling off around day 35
(Burgin et al., 1990). Plasmid pMM403 also contained a pBS backbone region of
approximately 3,000 base pairs (bp). The pBS region contained an ampicillin-resistance
gene, which was taken advantage of during cloning procedures. This plasmid was linearized
using NotI (NEB, Ipswich, MA) and dephosphorylated with Antarctic Phosphatase (NEB,
Ipswich, MA) in order to aid in ligation of the CaV1.3HA sequence. All enzymes were used
according to standard protocol. The linearized and dephosphorylated promoter sequence was
then gel-purified according to kit instructions using the SNAP UV-Free Extraction Kit
(Invitrogen, Carlsbad, CA).
The transgene was located on plasmid pBCM04, flanked by synthetic 3’ and 5’
UTRs. The CaV1.3 transgene, a generous gift from I. Bezprozvanny (University of Texas,
TX), was derived from rat CaV1.3 cDNA and tagged on an extracellular loop of the second
transmembrane domain with an HA epitope as previously described (Zhang et al., 2006).
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Characterization of the epitope-tagged CaV1.3 sequence demonstrated that the recombinant
protein is functional (Zhang et al., 2006). Synthetic 5’ and 3’ UTRs were inserted flanking
the CaV1.3HA transgenic cDNA in order to help stabilize mRNA and increase transgene
gene expression during the transcription process (Callis et al., 1987).
The transgene-synthetic UTR sequence was extracted from pBCM04 by digesting
with NotI (NEB, Ipswich, MA) and gel-purifying the 7218bp fragment using the SNAP UVFree Extraction Kit (Invitrogen, Carlsbad, CA). The purified DNA fragments from pMM403
and pBCM04 were ligated using T4 DNA Ligase (NEB, Ipswich, MA) and transformed into
Escherichia coli DH5α Subcloning Efficiency Competent Cells (Invitrogen, Carlsbad, CA).
The transformation was performed according to the Invitrogen protocol. Colonies from
transformations were plated and grown overnight on LB-ampicillin (100µg/mL) plates and
were then grown overnight in 3mL LB-ampicillin (100µg/mL). DNA was extracted using the
Qiaprep Spin Miniprep Kit (Qiagen, Valencia, CA) and analyzed using Not1 (NEB, Ipswich,
MA) to check for transgene insertion, and HindIII (NEB, Ipswich, MA) digestions to check
for insertion orientation. All mini-preps were performed according to the Qiaprep protocol.
Additionally, plasmid DNA was sent to the University of Michigan Sequencing Core with
plasmid-specific primers to ensure the final DNA sequence was correct.
The resulting plasmid, containing the αCaMKII promoter, 3’ and 5’ synthetic UTRs,
as well as the CaV1.3HA sequence, was called pJNS01 (Figure 1A). The 50µg of transgene
needed for injection was obtained from approximately 50 Qiaprep Spin mini-preps as
opposed to a single maxi-prep, due to the large size of pJNS01 (18kb), which inhibited
bacterial growth. DNA was linearized for injection using SfiI (NEB, Ipswich, MA), and the
injection sequence of approximately 15kb was purified using the SNAP UV-Free Extraction
12

Figure 3. CaV1.3HA transgenic construct and diagnostic cuts. A. Diagram of plasmid
pJNS01, containing the 5’ UTR region of the αCaMKII promoter, 5’ intron (UTR), CaV1.3
transgene, 3’ intron and pBS backbone. Locations of Not1 and SfiI restriction sites are
labeled. The NotI sites indicate where the CaV1.3 transgene was inserted into the αCaMKII
promoter-containing plasmid, pMM403 (not shown). The SfiI sites indicate where the pBS
backbone was removed to linearize the transgene. B. Diagnostic cuts of the final transgenic
construct (pJNS01). (Left) The NotI cut shows the 12.8kb band containing the αCaMKII
promoter fragment, as well as the 7.2kb band containing the CaV1.3 transgene fragment.
(Right) Uncut pJNS01 (U) and a SfiI cut of pJNS01 showing the linearized transgene at 15kb,
with the pBS backbone at 3kb. A Lambda-HindIII digest high-base pair ladder was used in
both gels (Takara, Japan).
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Kit (Invitrogen, Carlsbad, CA). 50µg of DNA was sent to the University of Michigan
Transgenic Core for injection into C57/B6 female mice. Transgenic injection occurs at
random; therefore, the locus of transgene integration is unknown in the resulting transgenic
mice.
Genotyping
Transgenic mice were maintained on a C57/B6NTac background (Taconic
Laboratories, Cambridge City, IN). Tail samples were digested overnight at 55oC in OneStep Tail Buffer (50mM KCL, 10mM Tris-HCL pH 9.0, 0.1% Triton X-100, 0.15mg/mL
Proteinase K). Polymerase chain reaction (PCR) was performed using Titanium Taq
Polymerase (Clontech Laboratories, Mountain View, CA) at the following parameters: initial
denaturation for 3:00 at 94oC, 30 cycles (0:45 at 94oC, 0:45 at 62oC, 0:45 at 72oC), and final
elongation of 5:00 at 72oC. Genotyping was performed using the transgene primers Fg3
(CCCCGAGGCTACCATCACC) and R2 (AGCCATGTACGTAGCCATCC) (~1000bp)
(Figure 2A), as well as wild-type primers β-actin Right (CTCTCAGCTGTGGTGGTGAA)
and β-actin Left (GCTCCCATTCATCAGTTCCATAGGT) (~250bp). Transgene primers
were specifically designed on two separate exons of the CaV1.3 sequence, in order to ensure
that endogenous CaV1.3 DNA would not be detected during the PCR process.
RNA Analysis
Mice were anesthetized using Isoflurane (MWI, Meridian, ID), and brains were
removed and dissected into cortex, hippocampus, and cerebellum. RNA was extracted from
the brain regions using Trizol Reagent (Invitrogen, Carlsbad, CA) according to
manufacturer’s directions. RNA purity and concentration were determined using a NanoDrop
14

Figure 4. PCR primers and HA-tag locations on the CaV1.3HA transgene. A. Diagram
of the linearized CaV1.3HA transgenic construct, showing the locations of the forward and
reverse PCR primers used for reverse transcription PCR (HA RT F and HA RT R), and
genotyping (Fg3 and R2). B. Diagram of CaV1.3, showing the location of the HA tag on the
second extra-cellular loop of domain two in the four-domain transmembrane calcium
channel.
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spectrophotometer (Thermo Scientific, Waltham, MA). Any residual DNA in each sample
was eliminated using DNaseI (Invitrogen, Carlsbad, CA). Contamination of residual DNA
was tested using reverse-transcription controls.
Reverse transcription was performed using SuperscriptIII First-Strand Synthesis
System according to manufacturer’s directions (Invitrogen, Carlsbad, CA). PCR on cDNA
samples was performed using Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA)
and the following parameters: initial denaturation for 2:00 at 94oC, 40 cycles (0:15 at 94oC,
0:30 at 55oC, 1:00 at 70oC). Genotyping for cDNA used the transgene primers HA RT F
(ACACAGACGCGTCACTATCC) and HA RT R
(TGACACCAGAGACACCCCAACGAC) (~1000bp) (Figure 2A), as well as wild-type
primers β-actin Right (CTCTCAGCTGTGGTGGTGAA) and β-actin Left
(GCTCCCATTCATCAGTTCCATAGGT) (~250bp). Reverse transcription PCR primers
were designed to include the 3’ synthetic intron, so that they would not detect endogenous
CaV1.3 reverse-transcribed mRNA.
Western Blot Analysis
Western blotting was performed using membrane fractions in order to examine
proteins embedded in the neuronal membrane. To obtain membrane fractions, mice were
anesthetized using Isoflurane (MWI, Meridian, ID) and the brain was removed, glued to the
bottom of a Petri dish, and then covered with ice-cold phosphate-buffered saline (PBS:
0.02M phosphate, 0.15M NaCl, pH 7.4). The brain was dissected into the hippocampus, the
cortex, and the cerebellum. Each sample was covered with 500µL of ice-cold HEPES sucrose
EDTA (HSE: 10mM HEPES, 350mM Sucrose, 5mM ETDA) with one tablet of Compete
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Mini Protease Inhibitor (Roche, Indianapolis, IN). Samples were homogenized with a pestle
and centrifuged at 4oC for 5 minutes at 2000xg. The supernatant and a high-sucrose buffer,
HSE, were placed in a 10.4mL Nalgene Oakridge ultracentrifuge tube (Thermo Fisher
Scientific, Rochester, NY). Samples were spun at 100,000xg for 1 hour. The supernatant was
removed and the pellet resuspended in 200µL HSE with one tablet of Complete Mini
Protease Inhibitor (Roche, Indianapolis, IN) and 1% Triton X to solubilize membranes and
release membrane proteins.
Protein quantification was performed using the Quick Start Bradford Protein Assay
(BioRad, Hercules, CA) according to the manufacturer’s directions. Samples were prepared
for Western Blotting by mixing 1:2 with Laemmli Buffer (BioRad, Hercules, CA) containing
β-mercaptoethanol. Samples were then heated for five minutes at 95oC to denature the
protein. Between 20µg and 30µg of protein were loaded per lane in a 7.5% SDSpolyacrylamide gel (BioRad, Hercules, CA). For detection of the recombinant protein, mouse
anti-HA (Covance, Princeton, NJ) was used at dilution of 1:1000 in water. Endogenous
CaV1.3 was detected using rabbit anti-CaV1.3 (1:3000) as previously described (Jenkins et
al., 2010). The CaV1.3 antibody was a kind gift from A. Lee (University of Iowa, IA). The
loading control used in all Western blots was mouse anti-Transferrin (Invitrogen, Carlsbad,
CA) used at a dilution of 1:500. Secondary antibodies used were horseradish-peroxidase
conjugated (HRP) goat anti-mouse and HRP goat anti-rabbit (Roche, Indianapolis, IN).
Western blots were visualized using Amersham Prime ECL (GE Healthcare, Waukesha, WI)
and exposed for between 10s and 5min. Film was then developed using a Kodak developer
(Eastman Kodak, New Haven, CT).
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Behavioral Subjects
Mice used for behavioral experiments were moved to a holding room near behavior
testing facilities at least a week before the start of testing. All animals were fed ad libitum
and kept on a schedule of 14 hours light: 10 hours dark. Testing was performed at
approximately the same time each day, during the animals' light cycle. CaV1.3HA line 102
transgenic mice and age-matched wild-type siblings were between the ages of 4 and 4.5
months. CaV1.3HA line 103 transgenic mice and age-matched wild-type siblings were
between the ages of 2 and 5 months. All animals were housed and cared for according to
University of Michigan and the University Committee on Use and Care of Animals
(UCUCA) guidelines. All experiments were approved by UCUCA on protocol #08768
(Appendix E).
Rotarod
Mice were placed on a rotating rod (UGO Basile Accelerating Rotarod, Collegeville,
PA) in squads of five. Mice were separated by dividers attached to the rotarod. The rotarod
accelerated from 4 to 40rpm over the course of five minutes. Latency to fall was recorded as
the time when the mouse made a full rotation or fell off the rotating rod. Mice were given
one trial per day over a five-day period, with a five-minute maximum time of trial.
Open Field
The open field was a 71x71x30cm white acrylic box placed in a room lit by indirect
white light. Mice were singly placed in the center of the box and allowed to explore for five
minutes. The field was divided into a center and a peripheral zone. Exploration was recorded
using a video camera (Olympus, Center Valley, PA). The total distance traveled as well as
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the distance traveled in each zone was calculated using LimeLight 2 tracking software
(Actimetrics, Evanston, IL).
Light/Dark Box
The light/dark box was a 46cm box placed in a room lit by indirect white light. The
box was divided into two zones, a dark zone, made of black acrylic with a black lid, and a
light zone, which was open at the top. The light zone was two times the length of the dark
zone. A small opening was cut in the center of the black acrylic wall separating the two
zones. Mice were singly placed in the center of the light zone and allowed to explore for five
minutes, and exploration was recorded using a video camera. The total distance traveled in
each zone as well as the number of transitions between the light and dark zones was
calculated using LimeLight 2 tracking software (Actimetrics, Evanston, IL).
Data Analysis
Kodak 1D software (Eastman Kodak, New Haven, CT) was used to analyze pixel
density of Western blot images. Data collected from behavioral experiments were exported
from LimeLight 2 software and imported into StatView (SAS Institute Inc., Cary, NC) or
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). All graphs were made using
GraphPad Prism 5. Statistical significance (α = .05, p < 0.05) was obtained using Student’s ttest or repeated measures ANOVA, as appropriate.
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RESULTS
Molecular Characterization
Transgene construct assembly
The CaV1.3HA transgene was created from two separate plasmids, pBCM04 and
pMM403. The 5’UTR-CaV1.3 Transgene-3’UTR was excised from pBCM04 using NotI and
ligated into pMM403, the promoter-containing plasmid. As shown in Figure 1B, a NotI
diagnostic cut of pJNS01 contains the 5’UTR-CaV1.3 Transgene-3’UTR fragment at 7,200bp
and the αCaMKII promoter-pBS fragment at 12,800bp. The transgene was linearized via a
SfiI cut, removing the pBS backbone fragment at 3,000bp and linearizing the CaV1.3HA
transgene at 15,000bp (Figure 3B).
Mice
The linearized transgene construct was sent to the University of Michigan Transgenic
Core for injection into pronuclear oocytes of a C57/B6 female mouse to generate transgenic
pups. As shown in Figure 5, six of eighteen mice obtained from the transgene injection were
genotyped as positive for the CaV1.3HA transgene. The six mice positive for the transgene,
hereafter referred to as founders, were each given a number (100-105) and paired with a
C57/B6Tac mouse of the opposite sex. Four of the initial founding mice were male, and two
were female. Female transgenic mice were unable to produce viable progeny, whereas all
four founding males produced pups that lived to be weaned. This result may indicate a high
copy number of transgene or unviable locus of transgene injection in the female transgenic
mice. The CaV1.3HA transgene was detected in the progeny of three of the four founding
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1000bp

Figure 5. Multiplex PCR of CaV1.3HA founding mice. A band at 1000bp indicates the
presence of the CaV1.3HA transgene in tail DNA from six of the eighteen live pups obtained
from transgene injection at the University of Michigan Transgenic Core. Each positive
mouse was labeled with a founding line number (100-105). A single copy of the CaV1.3HA
transgene-containing plasmid, pJNS01, was used as a positive control (+). The band at 230bp
indicates the presence of β-actin in all tail samples. A 1000bp ladder was used for reference.
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males. Upon further molecular characterization, only two founding lines (102 and 103)
expressed the recombinant protein. Further analysis of lines 102 and 103 determined that
both lines exhibit normal motor performance and exploratory behavior. These founding data
are summarized in Table 1. Initial molecular characterization of the CaV1.3HA mice focused
on line 102 based on results of concurrently performed behavioral experiments (not shown).
Molecular characterization of CaV1.3HA line 103 will be performed in the future.
RT-PCR (Reverse-Transcriptase Polymerase Chain Reaction)
To determine if the CaV1.3HA transgene inserted into the genome of founding line
102 was functional and transcribed into RNA, RT-PCR was performed on RNA samples
from brain tissue. Reverse-transcriptase PCR is used to synthesize and amplify cDNA from
messenger RNA (mRNA) via the enzyme reverse-transcriptase. RNA was isolated from
cortex, hippocampus, and cerebellum tissue samples obtained from a mouse positive for the
CaV1.3HA transgene, as well as a wild-type counterpart. After reverse-transcription, the
resulting cDNA samples from each brain region were amplified in a PCR reaction using the
primers shown in Figure 4A. As shown in Figure 6, PCR amplification of cDNA in brain
tissue samples revealed CaV1.3HA transgene expression in the cortex, hippocampus, and
cerebellum of the CaV1.3HA positive animal. There was no CaV1.3HA transgene expression
in the wild-type animal.
Western blot analysis
Western blot analysis was performed on membrane fractions of mouse cortex,
hippocampus, and cerebellum to determine CaV1.3HA recombinant protein presence.
Membrane fractions were used to examine the parts of the cell containing CaV1.3HA protein.
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Founding
Line

Sex of
Founder

Progeny?

Weaned
Progeny?

Transgene in
Progeny?

100
101
102
103
104
105

Male
Male
Male
Male
Female
Female

+
+
+
+
+
-

+
+
+
+
NA

+
+
+
NA
NA

Transgenic
Protein in
Progeny?
NA
+
+
NA
NA

Normal
Behavioral
Phenotype?
NA
NA
+
+
NA
NA

Table 1: CaV1.3HA Founding Mice. This table presents the breeding, molecular and
behavioral characteristics of each founding line of mice. Each line was examined for
successful breeding, which included having progeny and the progeny living until the age of
weaning, twenty-one days. Progeny of each founding line were genotyped to determine if the
transgene was present. The progeny of founding lines containing the transgene were then
tested for recombinant protein presence using Western blot analysis. Founding lines
containing the recombinant protein were examined for a normal behavioral phenotype using
a series of neurobehavioral tests. Results are marked as + (yes/positive), - (no/negative) and
NA (not applicable).
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1000bp

250bp

Figure 6. RT-PCR of CaV1.3HA expression in different brain regions. The bands on the
left indicates the presence of the CaV1.3HA at 1000bp in the cortex (ctx), hippocampus (hip)
and cerebellum (cbm) of the line 102 CaV1.3HA positive (+) mouse. No bands are present in
the line 102 CaV1.3HA age-matched wild type sibling (-). The bands on the right control for
reverse transcription, indicating the presence of β-actin at 250bp in each sample. Controls
were conducted by excluding reverse-transcriptase from each sample (not shown). A 100bp
ladder from Promega was used for reference.
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The location of the HA-tag on the CaV1.3 protein is shown in Figure 4B. The tag is located
on the extracellular side of second domain of the protein (Zhang et al., 2006). As seen in
Figure 7, a Western blot probing for the HA epitope on the CaV1.3 gene shows CaV1.3HA
expression in the cortex and hippocampus of transgenic animals. The recombinant protein is
found at 250kD and is approximately the same size as endogenous CaV1.3. A lack of
CaV1.3HA expression in the cerebellum is accounted for by the forebrain specificity of the
αCaMKII promoter. The blot was also probed with anti-transferrin as a control for protein
loading.
Figure 8 shows a Western blot using an antibody against endogenous CaV1.3. The
blot indicates the presence of CaV1.3 in the cortex, hippocampus, and cerebellum of both a
transgenic and wild-type animal. However, there appears to be significantly more CaV1.3
protein in the cortex and hippocampus of the transgenic animal. This is presumably due to
the CaV1.3 antibody detecting both the endogenous as well as overexpressed protein.
To further examine the overexpression of the CaV1.3 protein in transgenic animals,
cortex samples were analyzed from four transgenic and four wild-type animals (Figure 9A).
Pixel density of each protein band (CaV1.3 and transferrin) was calculated using Kodak1D
software. The resulting blot was subjected to densitometric analysis, normalizing the pixel
density of CaV1.3 to the pixel density of the loading control in each animal to generate a ratio
of CaV1.3 expression. The ratio for all wild-type animals was averaged, and then each
CaV1.3:transferrin ratio was normalized to this value. Figure 9B shows the comparison of
average data from the transgenic group of animals and wild-type animals. Animals positive
for the CaV1.3HA transgene were found to have approximately twenty percent more (p =
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Figure 7. Hybrid Western blot of CaV1.3HA and Transferrin expression. The Covance
mouse antibody against the HA tag (anti-HA) was used initially, then the membrane was
stripped and reprobed with mouse anti-transferrin (anti-Tfer), a transmembrane protein found
throughout the brain. The presence of the 250kD CaV1.3HA protein can be noted in the
cortex (ctx) and hippocampus (hip) of the line 102 CaV1.3HA positive animal (+). Human
embryonic kidney (hek) cells were transfected with CaV1.3HA DNA and were used as a
control for the HA antibody.
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Figure 8. Western blot of CaV1.3 expression. A rabbit anti-CaV1.3 (anti-1.3) antibody was
used initially, then the membrane was stripped and reprobed using mouse anti-transferrin
(anti-Tfer). A CaV1.3 knockout mouse (ko) was used as a control for the antibody. The line
102 mouse positive for CaV1.3HA (+) had more CaV1.3 in its cortex (ctx) and hippocampus
(hip) than its wild-type counterpart (-). An equal amount of CaV1.3 was found in the
cerebellum (cbm) of both animals. The band at 250kD indicates the presence of CaV1.3 and
the band at 95kD indicates the presence of transferrin, a ubiquitous membrane protein.
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Figure 9. Relative CaV1.3 expression in CaV1.3HA mice. A. Membrane fractions from the
cortex of four line 102 CaV1.3HA positive (+) and four CaV1.3 negative (-) were used to
examine relative CaV1.3 overexpression in transgenic mice. A rabbit anti-CaV1.3 (anti-1.3)
antibody was used initially, then the membrane was stripped and re-probed with mouse antitransferrin (anti-Tfer). Underlined +/- pairs indicate age-matched littermates. B. The
normalized band density (percentage of WT) of the CaV1.3:Transferrin bands were obtained
for each of the four CaV1.3 HA positive (HA+) and the four control (WT) mice from (A).
The normalized band density of HA+ mice was significantly more (*, p-value 0.02) than the
normalized band density of wild-type mice. Data are plotted as mean ± standard error of
mean (SEM).

28

0.02) CaV1.3 in their cortex than their wild-type counterparts. A membrane fraction sample
from a CaV1.3KO mouse was also probed with anti-CaV1.3 to ensure antibody specificity.
Neurobehavioral Analysis of CaV1.3HA Line 102
Rotarod
Mice were tested on the accelerating rotarod to analyze motor function. The test was
given for 300 seconds once a day over the course of five days. Mice with normal motor
function are anticipated to show an increased latency to fall during the training period. Figure
10 shows the data acquired over a five-day testing period for six CaV1.3HA positive mice
from the 102 line and four age-matched wild-type control animals. While both groups of
mice had relatively low performance on day one, by day five both groups had reached an
average of about 180 seconds on the rotarod before falling. There was no significant
difference between transgenic and wild-type animals (p = 0.12) during each trial. However,
performance of each group improved daily, and performance was significantly better on the
final day of testing than on the first (p < 0.0001). These results suggest that there is no deficit
in motor function due to CaV1.3 over-expression in founding line 102.
Open Field
The open field test was performed to determine overall exploratory and anxiety-like
behavior in CaV1.3HA mice. Eight CaV1.3HA-positive mice from line 102 and six wild-type
mice were individually placed for five minutes in the open field and allowed to freely
explore. As seen in Figure 11A, there was no difference in the total distance traveled per
group (p = 0.29). The distance traveled in the center versus the distance traveled in the
periphery was also examined, as shown in Figure 11B. Again, there was no significant
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Figure 10. Rotarod performance in line 102 CaV1.3HA mice. Six CaV1.3HA positive
(HA+) and four wild-type controls (WT) were trained for five days (300 second trials) on the
Rotarod. The latency to fall (s) was recorded for both groups of mice each day. Data are
plotted as mean ± standard error of mean (SEM).

30

B
5000

5000

4000

4000

WT
HA+

Distance (cm)

Total Distance (cm)

A

3000

2000

2000

1000

1000

0

3000

WT

HA+

0

Edge

Center

Figure 11. Open field performance in Line 102 CaV1.3HA mice. Five wild-type (WT) and
eight CaV1.3HA+ (HA+) mice were placed individually in the open field for five minutes. A.
The total distance traveled (cm) for WT and HA+ mice. B. The average distance traveled per
zone (cm), center and edge, for CaV1.3HA Line 102. Data are plotted as mean ± standard
error of mean (SEM).
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difference between the distances traveled in either zone between the groups (p = 0.22),
suggesting that the CaV1.3HA mice do not express an anxiety-like phenotype. However, both
groups traveled a significantly farther distance around the edge of the open field (p <
0.0001). Due to a tracking error, one wild-type mouse from group 102 was excluded in the
open field analysis. These results suggest that overexpression of CaV1.3 did not affect
exploratory and anxiety-like behaviors of transgenic mice.
Light/Dark Box
The final behavioral test performed was the light/dark box. This test assessed anxietylike and exploratory behavior in the CaV1.3HA mice. Eight CaV1.3HA positive mice from
line 102 and six wild-type counterparts were individually placed in the box for 300 seconds.
Data from the light/dark box are represented in Figure 12. Both transgenic and wild-type
animals avoided the light side of the box, spending significantly more time in the dark zone
(p < 0.0001) (Figure 12A). There was no difference between the genotypes in time spent in
either zone (p = 0.87). The number of crossings between the zones was also similar between
the transgenic and wild-type animals (p = 0.73) (Figure 12B). These results suggest that
CaV1.3 overexpressing mice exhibit normal behavior in the light/dark box.
CaV1.3HA Line 103 Neurobehavioral Analysis
Rotarod
Six CaV1.3HA positive mice from line 103 and seven wild-type controls were trained
for five days on the accelerating rotarod. Figure 13 shows the average latency to fall for each
group over five days of training. There was no statistically significant difference between
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Figure 12. Light dark box performance in line 102 CaV1.3HA mice. Six wild-type (WT)
and eight CaV1.3HA positive (HA+) mice were individually placed for 300 seconds in the
light dark box. A. The total time in zone (s) by each group. B. The number of transitions
between the light and dark zones per group. Data are plotted as mean ± standard error of
mean (SEM).
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Figure 13. Rotarod performance in line 103 CaV1.3HA mice. Six CaV1.3HA positive
(HA+) and seven wild-type controls (WT) were trained for five days (300 second trials) on
the RotaRod. The latency to fall (s) was recorded for both groups of mice each day. Data are
plotted as mean ± standard error of mean (SEM).
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genotypes on each day (p = 0.86). All mice performed significantly better over the course of
the five-day training period (p = 0.0005). These results suggest that overexpression of CaV1.3
does not affect motor function in CaV1.3HA line 103.
Open Field
Six CaV1.3HA positive mice from line 103 and seven wild-type controls were tested
in the open field. The total distance traveled for each group is shown in Figure 14A. There
was no significant difference in the distance traveled between the genotypes (p = 0.30). The
distance traveled in each zone is shown in Figure 14B. All mice traveled significantly more
in the edge zone than in the center zone (p < 0.0001). However, there was no difference
between the genotypes within each zone (p = 0.79). These results suggest that exploratory
and anxiety-like behaviors in CaV1.3HA line 103 are similar to that of wild-type mice.
Light Dark Box
Six CaV1.3HA positive and seven wild-type controls were tested for 300 seconds in
the light dark box. The total time spent per group in either the light or dark zone is shown in
Figure 15A. CaV1.3HA positive mice spent significantly less time in the dark zone than their
wild-type counterparts (p = 0.01). Both groups spent significantly more time in the dark zone
than in the light zone (p < 0.0001). The number of transitions between zones is shown in
Figure 15B. There was no difference in the number of transitions between zones per group (p
= 0.46). These results suggest that there is a slight difference in light dark box behavior in
CaV1.3 over-expressing mice compared to wild-type counterparts.
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Figure 14. Open field performance in line 103 CaV1.3HA mice. Seven wild-type (WT)
and six CaV1.3HA positive (HA+) mice were placed in the Open Field for 300s. A. The total
distance traveled (cm) for CaV1.3HA Line 103 B. The average distance traveled (cm) by WT
and HA+ animals in each of the two zones of the open field, edge and center. Data are plotted
as mean ± standard error of mean (SEM).
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Figure 15. Light/dark box performance in line 103 CaV1.3HA mice. Seven wild-type
(WT) and six CaV1.3HA positive (HA+) mice were individually placed for 300 seconds in
the light dark box. A. The total time (s) spent in each zone of the light dark box. B. The
number of transitions between the light and dark zones per group. Data are plotted as mean ±
standard error of mean (SEM).
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DISCUSSION
Biochemical and Molecular Characterization of CaV1.3HA Mice
CaV1.3HA transgenic mice were developed in order to mimic the putative increase in
CaV1.3 expression that may occur during aging in young animals. The first step in
characterization of these animals was to characterize transgenic CaV1.3HA expression.
The molecular characterization of CaV1.3HA animals explicitly examined the
CaV1.3HA transgene in RNA as well as in CaV1.3HA protein expression (Figures 6 and 7).
Furthermore, endogenous CaV1.3 expression in transgenic animals was also examined via
Western blot analysis, in order to determine the effect of CaV1.3 over-expression on
endogenous protein levels.
The αCaMKII promoter was used in the CaV1.3HA transgenic construct for two
reasons. Primarily, previous research using the promoter has shown localization of transgenic
proteins to the forebrain of transgenic animals (Mayford et al., 1996). Forebrain expression
of the transgenic protein marginalized the possibility that transgene expression in the
cerebellum would interfere with normal motor function. An additional benefit to using the
αCaMKII promoter is that its expression begins post-natally (Burgin et al., 1990). Therefore,
it was anticipated that transgenic mice would not experience problems that may arise from
transgenic expression during fetal development.
RNA expression of CaV1.3HA was anticipated in only the cortex and hippocampus of
transgenic brain tissue samples. RNA samples were treated with DNaseI, then reversetranscribed into cDNA and analyzed via PCR for transgene expression. The results obtained
from reverse-transcriptase PCR analysis demonstrated RNA presence in all three areas of the
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brain examined: the cortex, hippocampus, and cerebellum. In experiments characterizing
αCaMKII localization using in-situ hybridization, some expression of αCaMKII RNA was
discovered in the cerebellum of rats (Burgin et al., 1990). Expression of αCaMKII in the
cerebellum was very low compared to the expression in the forebrain. Interestingly,
expression in all areas of the brain increased over time (Burgin et al., 1990). In order to
determine if there is less expression of CaV1.3HA RNA in the cerebellum than in the
forebrain of transgenic mice, a quantitative analysis could be performed using real-time PCR.
After RNA analysis, localization of CaV1.3HA recombinant protein within the brain
was determined. In membrane fraction samples, CaV1.3HA recombinant protein was found in
the cortex and hippocampus of transgenic mice, but not in the cerebellum (Figure 7). This
result is similar to that of the initial characterization of transgenic protein localized to the
forebrain using the αCaMKII promoter (Mayford et al., 1996). This result further supports
the explanation that the expression of CaV1.3HA RNA found in the cerebellum of transgenic
animals was negligible. In addition, motor performance in both CaV1.3HA lines 102 and 103
was unimpaired, further indicating that any CaV1.3HA expression in the cerebellum was
insignificant.
Because CaV1.3HA transgenic mice were developed to overexpress CaV1.3 in the
forebrain, it was important to determine the effect on endogenous CaV1.3 protein expression
in the presence of the CaV1.3HA transgene. A possible outcome of CaV1.3 overexpression
was a down-regulation of endogenous CaV1.3 in areas where the transgene was expressed.
One caveat assessing endogenous CaV1.3 levels in CaV1.3HA overexpressing mice was that
the anti-CaV1.3 antibody detected the same epitope in both CaV1.3HA and CaV1.3 in
transgenic animals. This is because rat CaV1.3 (as used in the CaV1.3HA transgenic
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construct) and mouse CaV1.3 have similar protein sequences. Therefore, the Western blot
obtained using an anti-CaV1.3 antibody showed an increase in CaV1.3 protein expression in
the forebrain but not cerebellum of a transgenic mouse (Figure 8). This result supports that
the CaV1.3HA transgene was forebrain specific, and leads to a CaV1.3 over-expression in
transgenic animals. In the future, brain tissue samples from additional mice will be examined
to ensure results can be replicated. In addition, when cortical membrane fractions of four
CaV1.3HA positive and four wild-type mice were examined for the relative overexpression of
CaV1.3, the samples from transgenic mice had approximately 20% more CaV1.3 than wildtype mice (Figure 9).
Expression of CaV1.2 was not examined in this study. There could be downregulation in CaV1.2 expression compensating for the overexpression of CaV1.3. Although
down-regulation has not been examined directly, one experiment suggesting otherwise
examined the sAHP in both CaV1.2 and CaV1.3 knockout mice. The sAHP was diminished in
a knockout model of CaV1.3. However, the sAHP was not affected in a knockout model of
CaV1.2 (Gamelli et al., 2011). The change in the sAHP in the knockout model of CaV1.3
indicates that CaV1.2 expression is not up-regulated in order to compensate for the absence of
CaV1.3. This lack of compensation by CaV1.2 in CaV1.3 knockout models suggests that there
is no interaction between expression levels of CaV1.2 and CaV1.3. Therefore, it seems
unlikely that CaV1.2 expression would be down-regulated in order to maintain homeostatic
balance in the occurrence of CaV1.3 overexpression. In the future, protein expression of
CaV1.2 will be analyzed in CaV1.3 overexpressing mice in order to determine if CaV1.2
expression is affected in the up-regulation of CaV1.3.
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Another potential complication is that CaV1.2 expression may be up-regulated in
CaV1.3 over-expressing mice. This possibility would limit definitive conclusions made about
the specific role of CaV1.3 overexpression. However, any observed impairments found in
learning and memory tasks in these animals would be due to an overall up-regulation of
LVGCC expression, and thus would be in accordance with previous conclusions regarding
LVGCCs and aging.
CaV1.3HA Mice Exhibit Normal Motor Performance
One possible outcome of CaV1.3 overexpression in CaV1.3HA mice was a motor
deficit. To examine this possibility, mice were given five days of testing on the accelerating
rotarod. Both wild-type and CaV1.3 over-expressing animals from founding lines 102 and
103 improved in rotarod performance during the five days of testing. This result indicates
that CaV1.3HA mice do not have a motor deficit associated with over-expression of CaV1.3.
This result is encouraging and indicates that these mice may be used in the future in tasks
requiring unimpaired motor performance, such as the Morris water maze and the radial arm
maze (Murphy et al., 2006).
CaV1.3HA Mice Exhibit Normal Exploratory Behavior
In addition to data provided from rotarod performance, mice from both CaV1.3HA
line 102 and line 103 exhibit normal exploratory behaviors. In the open field, mice from both
lines traveled the same distance as their wild-type counterparts. This indicates a lack of overt
fear, anxiety-like or hyperactive behavior in the transgenic animals (McKinney et al., 2008).
However, it should be noted that transgenic mice as well as wild-type mice spent
significantly more time traveling along the edges than traveling in the center zone. The lack
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of travel in the center zone of the open field should not be considered a deficit or unusual
behavior in mice, as these animals are naturally fearful of open spaces (Murphy et al., 2006).
The final behavioral test performed in CaV1.3HA mice was the light/dark box. This
test is another examination of exploratory and fear behavior (McKinney et al., 2008). Both
CaV1.3HA lines 102 and 103 performed similarly in the test. While all mice spent
significantly more time in the dark side of the box, they all also traveled between the light
and dark sides between thirteen and eighteen times. This result demonstrates that the mice
are fearful of the more open space provided by the white side of the box but that they still
exhibit exploratory behavior and travel willingly between the two halves of the box.
Interestingly, CaV1.3HA line 103 transgenic animals spent significantly more time in
the light side of the light dark box than did their wild-type counterparts. However, this
difference was not large. Because other measures of CaV1.3HA line 103 demonstrate that the
line of mice does not exhibit overtly exploratory behavior, it is likely that this difference is
due to a small sample size.
CaV1.3HA Mice can be used as a Model of Aging
Current paradigms for studying age-related cognitive decline in animals have several
limitations. Aging studies are typically very lengthy, taking up to two years to obtain "aged"
rodents. The time course of aging is extremely costly in terms of both care and resource use.
In addition, there is no guarantee that animals will survive to reach an age appropriate to use
for these experiments.
Many age-associated changes occur simultaneously. It is difficult to assess the effects
of each change when studying a typical model of aging, because results can be confounded
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by other age-associated changes. For example, aged mice experience age-related hearing loss
and therefore cannot be tested in a fear learning paradigm using tone as a conditioned
stimulus (Keithley et al., 2004).
The transgenic mice that overexpress CaV1.3 address the above concerns of current
models of aging. Because transgene expression begins shortly after birth, the problems
associated with the length of time needed to conduct an aging study would be virtually
nonexistent. These mice only express a single change that appears to be associated with
aging. Therefore, any age-associated changes unrelated to learning and memory, such as
motor impairments or hearing loss, are unlikely to occur because these transgenic mice can
be studied at relatively young ages. This study has shown that CaV1.3HA mice do not exhibit
impaired mobility or motor function that often occur in typical models of aging. They also
appear to have similar exploratory behaviors as wild-type mice.
The results reported in this study indicate that in the future, CaV1.3HA mice can be
used successfully in various tasks examining learning and memory. Two tasks previously
demonstrated to be sensitive to aging are the radial arm maze and the Morris water maze
(Murphy et al., 2006). It is hypothesized that CaV1.3HA mice will exhibit deficits in these
memory and learning tasks similar to that of aged mice. Preliminary experiments have found
an altered behavioral phenotype in the Morris water maze in CaV1.3HA line 102 mice
(Moore, S., personal communication 2011).
In addition, CaV1.3HA mice can be used to determine the relative contribution of
CaV1.3 to the sAHP and neuronal excitability. Previous research indicated a decrease in the
sAHP of CaV1.3 knockout animals (Gamelli et al., 2011). A separate study demonstrated an
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increase in neuronal excitability in CaV1.3 knockout animals (McKinney et al., 2009). It is
anticipated that opposite effects on the sAHP and neuronal excitability will occur in CaV1.3
overexpressing animals. Electrophysiological experiments will be performed to determine if
CaV1.3HA mice exhibit an increase in the sAHP as compared to their age-matched
counterparts. It is hypothesized that an increase in the sAHP in CaV1.3HA mice will be
comparable to the sAHP increase observed in aged animals. Furthermore, it is likely that
CaV1.3HA mice will demonstrate a decrease in neuronal excitability similar to that
previously observed in aged animals.
The development of CaV1.3 overexpressing mice could expand the calcium
hypothesis of aging by demonstrating that an up-regulation in expression of a specific L-type
voltage-gated calcium channel, CaV1.3, contributes to altered intracellular calcium
homeostasis. By determining if CaV1.3 overexpression in young animals mimics the
increased sAHP and cognitive deficits found in aged animals, this line of mice could present
a significant contribution towards understanding the role of calcium dysregulation in the
underlying mechanisms of age-related cognitive decline.
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APPENDICES
Appendix A: Chemicals and Reagents
A
Agarose, Genepure LE

ISC, Kaysville, UT

Ampicillin

Sigma, St. Louis, MO

B
Beta-mercaptoethanol

Sigma, St. Louis, MO

Blotto, Non-fat Dry Milk

Santa Cruz, CA

Bovine Serum Albumin (BSA)

BioRad, Hercules, CA

Bradford Assay One-Step Reagent

BioRad, Hercules, CA

C
Complete Mini Protease Inhibitor

Roche, Indianapolis, IN

D
DNase/RNase Free Distilled Water

Gibco, Grand Island, NY

DNaseI

Invitrogen, Carlsbad, CA

dNTPs, 10mM

Promega, Madison, WI

E
EDTA, 0.5M

AccuGENE, Rockland, ME
48

Enhanced Chemiluminescence Kit, ECL Plus

Amersham, UK

Ethidium bromide

ISC, Kaysville, UT

G
Glycine

Roche, Indianapolis, IN

H
HEPES, 1.0M

Sigma, St. Louis, MO

HindIII

NEB, Ipswich, MA

I
Isoflurane

MWI, Meridian, ID

K
Kwik-Stop

Arc Labs, Atlanta,

GA

L
Ladder, 100bp

Promega, Madison, WI

Ladder, 1kb

Promega, Madison, WI

Ladder, Lambda-HindII digest

Takara, Japan

LB Broth

Invitrogen, Carlsbad, CA

LB-Agar

Invitrogen, Carlsbad, CA
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M
Methanol

Fisher, Fair Lawn, NJ

N
NotI

NEB, Ipswich, MA

P
Phenol:Chloroform:Isoamyl Alcohol

Invitrogen, Carlsbad, CA

Primers

Invitrogen, Carlsbad, CA

Proteinase K

Invitrogen, Carlsbad, CA

PVDF Membranes

BioRad, Hercules, CA

S
SDS-PAGE 7.5% Gels

BioRad, Hercules, CA

SfiI

NEB, Ipswich, MA

S.N.A.P UV-Free Gel Extraction Kit

Invitrogen, Carlsbad, CA

Sodium dodecyl sulfate (SDS)

Invitrogen, Carlsbad, CA

Sodium chloride, NaCl

Fisher, Fair Lawn, NJ

Sodium phosphate dibasic, Na2HPO4

Fisher, Fair Lawn, NJ

Sodium phosphate monobasic, NaH2PO4

Fisher, Fair Lawn, NJ
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Sucrose, C12H22O11

Fisher, Fair Lawn, NJ

SuperScriptIII First-Strand Synthesis System

Invitrogen, Carlsbad, CA

T
T4 DNA Ligase

NEB, Ipswitch, MA

TAE 50X Buffer

Fisher, Fair Lawn, NJ

Taq Polymerase

Clontech, San Jose, CA

Tris

Fisher, Fair Lawn, NJ

Tris base

Fisher, Fair Lawn, NJ

Tris-HCL

Fisher, Fair Lawn, NJ

Triton X-100

Merck, Batavia, IL

Trizol

Invitrogen, Frederick, MD

Tween

Invitrogen, Frederick, MD
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Appendix B: Antibodies
Anti-mouse HA Antibody

Covance, Battle Creek, MI

Anti-rabbit CaV1.3 Antibody

UofI, Iowa City, IA

Anti-mouse Transferrin Antibody

Invitrogen, Carlsbad, CA

HRP Goat anti-mouse

Roche, Indianapolis, IN

HRP Goat anti-rabbit

Roche, Indianapolis, IN
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Appendix C: Buffers and Solutions
LB Broth

LB broth base
H2O

20g
Bring to 1L

LB-Amp Plates

LB agar
H2O
Ampicillin (100mg/mL)

32g
Bring to 1L
1mL

Tail Digestion Buffer 1-Step

KCl
Tris-HCl pH 9
Triton X-100
H2O

1.86g
1.55g
0.5mL
Bring to 1L

HEPES-Sucrose EDTA (HSE)

1M HEPES buffer
0.5M EDTA
Sucrose
H2O

1mL
0.5mL
12g
Bring to 100mL

HSE + protease inhibitor

HSE
10mL
Protease Inhibitor Complete 1 tablet

Resuspension Buffer

HSE + protease inhibitor
Triton X-100

10mL
10µL

10X Phosphate-Buffered Saline

NaH2PO4
Na2HPO4
NaCl
H2O

2.28g
11.5g
43.84g
Bring to 500mL

1X PBS-0.1% Tween

10X PBS
Tween
H2O

25mL
250µL
225mL

Blocking Solution

1X PBS-Tween
Blotto

40mL
2.0g

Laemmli Buffer: 950uL 2:1

Laemmli Buffer
β-Mercaptoethanol

950µL
50µL

10X Western Blot Running Buffer

Tris
Glycine
SDS
H2O

30.3g
144g
10g
Bring to 1L
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10X Western Blot Transfer Buffer

Tris
Glycine
H2O

30.3g
144g
Bring to 1L

1X Western Blot Transfer Buffer

10X Transfer buffer
Methanol
H2O

100mL
100mL
800mL

10% SDS

SDS
H2O

10g
100mL

Stripping buffer

Glycine
10% SDS
H2O
pH to 2.0

144g
10mL
Bring to 1L
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Appendix D: Software and Databases
Adobe Acrobat

Adobe Systems, San Jose, CA

Adobe Photoship CS

Adobe Systems, San Jose, CA

EndNote 5.0

ISI Research Software, Berkely, CA

Entrez, PubMed

http://www.ncbi.nlm.nih.gov/entrez

Filemaker Pro 7.0

Filemaker Inc., Santa Clara, CA

GraphPad Prism 5.0

GraphPad, San Diego, CA

Kodak 1D Scientific Imaging Software

Kodak, Rochester, NY

Limelight

Actimetrics, Wilmette, IL

Microsoft Office 10

Microsoft, Redmond, WA

Statview 5.0

SAS Institute, Cary, NC
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Appendix E: IACUC Approval
This project was approved for the use of animals by the University Committee for the Use
and Care of Animals (UCUCA) at the University of Michigan under approval number 08768
as of 11/20/2009. The University’s Animal Welfare Assurance Number on file with the
National Institute of Health’s (NIH) Office of Laboratory Animal Welfare (OLAW) is
A3114-01.
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